Cargando…

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11

The AWARD‐11 trial demonstrated the safety and efficacy of dulaglutide 3.0 and 4.5 mg compared to dulaglutide 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. This post hoc analysis examined the change from baseline in glycated haemoglobin (HbA1c) and proportions of pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frias, Juan P., Bonora, Enzo, Cox, David A., Bethel, M. Angelyn, Kwan, Anita Y.M., Raha, Sohini, Malik, Raleigh E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292947/ https://www.ncbi.nlm.nih.gov/pubmed/34463420 http://dx.doi.org/10.1111/dom.14533

Ejemplares similares

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
por: Kwan, Anita Y.M., et al.
Publicado: (2022)

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
por: Bonora, Enzo, et al.
Publicado: (2021)

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
por: Gallwitz, Baptist, et al.
Publicado: (2017)

Glycated haemoglobin (HbA(1c)) for postmortem diagnosis of diabetes
por: Lepik, Delia, et al.
Publicado: (2018)

Labile glycated haemoglobin and carbamylated haemoglobin are still critical points for HbA(1c) measurement
por: Desmons, Aurore, et al.
Publicado: (2017)

Glycated Haemoglobin (HbA1c) Variations in Nondiabetics With Nutritional Anemia
por: Pilla, Rakesh, et al.
Publicado: (2020)

Glycated haemoglobin (HbA1c) in mid-pregnancy and perinatal outcomes
por: Carlsen, Ellen Ø, et al.
Publicado: (2022)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
por: Dungan, K. M., et al.
Publicado: (2016)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Variability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time
por: Fryer, Anthony A., et al.
Publicado: (2022)

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
por: Yu, Miao, et al.
Publicado: (2020)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

Glycated haemoglobin (HbA(1c)) and fasting plasma glucose relationships in sea‐level and high‐altitude settings
por: Bazo‐Alvarez, J. C., et al.
Publicado: (2017)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

Elevated Glycated Haemoglobin (HbA1c) Is Associated with an Increased Risk of Pancreatic Ductal Adenocarcinoma: A UK Biobank Cohort Study
por: McDonnell, Declan, et al.
Publicado: (2023)

HbA1c and brain health across the entire glycaemic spectrum
por: Garfield, Victoria, et al.
Publicado: (2021)

The impact of the HbA1c level of type 2 diabetics on the structure of haemoglobin
por: Ye, Shaoying, et al.
Publicado: (2016)

Diabetic control and compliance using glycated haemoglobin (HbA1C) testing guidelines in public healthcare facilities of Gauteng province, South Africa
por: Kone, Ngalulawa, et al.
Publicado: (2023)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

Glycated haemoglobin A(1c) (HbA(1c)) for detection of diabetes mellitus and impaired fasting glucose in Malawi: a diagnostic accuracy study
por: Rathod, Sujit D, et al.
Publicado: (2018)

The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study
por: Fang, Hao Sen Andrew, et al.
Publicado: (2022)

Glycated Haemoglobin (HbA1c) and Future Physical and Mental Functional Health in the European Prospective Investigation into Cancer (EPIC)-Norfolk Population-Based Study
por: McLachlan, Fiona, et al.
Publicado: (2023)

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
por: Giorgino, Francesco, et al.
Publicado: (2019)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

Associations between HbA(1c) and continuous glucose monitoring‐derived glycaemic variables
por: Hirsch, I. B., et al.
Publicado: (2019)

Stability of glycated haemoglobin (HbA1c) measurements from whole blood samples kept at −196°C for seven to eight years in The Malaysian Cohort study
por: Abdullah, Noraidatulakma, et al.
Publicado: (2023)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Glycated Haemoglobin Is Inversely Related to Serum Vitamin D Levels in Type 2 Diabetic Patients
por: Zoppini, Giacomo, et al.
Publicado: (2013)

Glycated Hemoglobin (HbA1c): Clinical Applications of a Mathematical Concept
por: Leow, Melvin Khee Shing
Publicado: (2016)

Haemoglobin switching modulator SNPs rs5006884 is associated with increased HbA(2) in β-thalassaemia carriers
por: Cyrus, Cyril, et al.
Publicado: (2019)

Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
por: Pantalone, Kevin M., et al.
Publicado: (2018)

Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
por: Jódar, Esteban, et al.
Publicado: (2021)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

Variables Involved in the Discordance between HbA1c and Fructosamine: The Glycation Gap Revisited
por: Zafon, Carles, et al.
Publicado: (2013)

Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy
por: Casadei, Giulia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9l9fme9455sau922l6h5o1ta13